The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study
Year: 2023
Type: article
Abstract: The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase 2, open-label DIALOG study. In this final analysis, long-term efficacy and safety are presented for patients who completed 66 cycles (of 28 days) of treatment with nilotinib (230 mg/m2 twice daily) or discontinued early. Overall, 59 patients were enrolled and 58 were treated (R/I, n = 33; ND, n = 25; median time on treatment: 60.5 and 51.9 months, respectively). In the R/I cohort, the cumulative major molecular response (MMR; BCR::ABL1 international scale [IS] ≤ 0.1%) rate was 60.6%, and no patients had a confirmed loss of MMR. Among ND patients, the best overall MMR rate was 76.0%; 3 patients had a confirmed loss of MMR. The cumulative molecular response MR4 (BCR::ABL1IS ≤ 0.01%) and MR4.5 (BCR::ABL1IS ≤ 0.0032%) rates by 66 cycles were 27.3% and 12.1% in the R/I cohort, and 56.0% and 44.0% in the ND cohort, respectively. The safety profile of nilotinib was consistent with those of earlier reports. No on-treatment deaths occurred. These long-term (up to ∼5 years) data support the efficacy and safety of nilotinib in pediatric patients with Ph+ CML-CP. This trial was registered at www.clinicaltrials.gov.uk as #NCT01844765.
Source: Blood Advances
Authors: Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Briana C. Patterson, Jill Samis, Miguel Izquierdo, Ksenia Titorenko, Sai Li, Darintr Sosothikul
Institutions: Columbia University Irving Medical Center, Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, University of Milano-Bicocca, Keio University, Istituto Giannina Gaslini, Kanagawa Children's Medical Center, Seoul National University, Seoul National University Children's Hospital, Nationwide Children's Hospital, The Ohio State University, Istanbul University-Cerrahpaşa, Istanbul University, Hospital Infantil Universitario Niño Jesús, Princess Máxima Center, Hôpital Pellegrin, Samsung Medical Center, Sungkyunkwan University, Erasmus MC - Sophia Children’s Hospital, Inserm, Centre Hospitalier Universitaire de Poitiers, Emory University, Children's Healthcare of Atlanta, Lurie Children's Hospital, Novartis (Switzerland), Novartis (Germany), Chulalongkorn University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W4386955073
